Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.
about
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerCutaneous complications of molecular targeted therapy used in oncologyCutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 PatientsImmune biomarkers of anti-EGFR monoclonal antibody therapyCA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Xerosis and pruritus as major EGFRI-associated adverse events.Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case reviewDermatologic events from EGFR inhibitors: the issue of the missing patient voice.Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin ToxicitiesThe incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.
P2860
Q26747335-ECB2B8AF-5628-4208-B8AA-CB08BC16B94DQ28070095-D9DE1D6C-A336-4D63-8FD6-A92FAAC271EDQ29248067-3EED7927-3FB9-4714-9CE5-BFE124491E79Q34723594-B1F348CF-1DF8-4A34-9053-6BB1425F610FQ36012730-4F8B266B-693A-41DC-A44D-ED22A34D0330Q36400206-7B698E68-6950-4214-AE23-FEADA72C8495Q37369678-312F1DE5-609A-4976-AA90-D30E69CFD5B3Q37541523-9C1E2579-C1CA-4CD2-9D35-16CCF251E5DDQ37644848-35016534-A3B4-4330-BDE5-57CCAB445265Q38410471-446B0B42-6D26-426E-87BA-F349059E3BCFQ41018872-15AB56EE-5B1A-48DD-A43B-5E65F1F586A8Q41835826-8404D854-09ED-4C69-94DB-EC50D5EEAAA7Q54982443-006AA5DA-5FD8-4405-899E-0311A89273B5
P2860
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dermatologic Toxicities from M ...... athophysiology and Management.
@ast
Dermatologic Toxicities from M ...... athophysiology and Management.
@en
type
label
Dermatologic Toxicities from M ...... athophysiology and Management.
@ast
Dermatologic Toxicities from M ...... athophysiology and Management.
@en
prefLabel
Dermatologic Toxicities from M ...... athophysiology and Management.
@ast
Dermatologic Toxicities from M ...... athophysiology and Management.
@en
P2860
P356
P1476
Dermatologic Toxicities from M ...... Pathophysiology and Management
@en
P2093
Bilal Piperdi
Shaad E Abdullah
P2860
P304
P356
10.1155/2012/351210
P577
2012-09-11T00:00:00Z